Our Companies
COMPANY PROFILE
Enable next-generation cancer therapies through the stable supply of radioactive isotopes (Ac-225)
NovAccel is a startup dedicated to the development of manufacturing technologies for medical radioactive isotopes, aiming to enable the practical application of next-generation cancer therapies such as Targeted Alpha Therapy (TAT).
TAT is a promising treatment modality that delivers highly potent alpha radiation emitted from drugs selectively accumulated in cancer cells, offering strong therapeutic efficacy. However, a global shortage of its key radioactive isotope, Actinium-225 (Ac-225), has become a major bottleneck to its widespread adoption.
NovAccel’s compact superconducting accelerator, designed at a scale of approximately 10 meters, combines small size with high efficiency, enabling a more stable and scalable supply of Ac-225 compared to conventional production methods.
Through this approach, NovAccel aims to establish a sustainable supply system that supports the entire value chain, from drug development to clinical application.
TAT is a promising treatment modality that delivers highly potent alpha radiation emitted from drugs selectively accumulated in cancer cells, offering strong therapeutic efficacy. However, a global shortage of its key radioactive isotope, Actinium-225 (Ac-225), has become a major bottleneck to its widespread adoption.
NovAccel’s compact superconducting accelerator, designed at a scale of approximately 10 meters, combines small size with high efficiency, enabling a more stable and scalable supply of Ac-225 compared to conventional production methods.
Through this approach, NovAccel aims to establish a sustainable supply system that supports the entire value chain, from drug development to clinical application.
COMPANY STORY
Origin
With Mr. Yamashita’s experience in international collaborations at CERN and large-scale accelerator projects, a multidisciplinary team of physicians, physicists, engineers, and business leaders founded NovAccel in 2024.
Strength
Building on the expertise of Dr. Hayano, who has worked on the development of superconducting accelerators such as the TRISTAN accelerator and linear collider projects at KEK, NovAccel has independently developed a compact superconducting accelerator of approximately 10 meters, optimized for medical applications.
This enables the stable production of high-quality Ac-225 from small amounts of raw materials, while keeping facility costs low and allowing for stepwise expansion of production capacity.
This enables the stable production of high-quality Ac-225 from small amounts of raw materials, while keeping facility costs low and allowing for stepwise expansion of production capacity.
UTEC’s value add
Support across government relations, financing, business development, and team building
-
Compact Superconducting Accelerator “RiSA”
-
Therapeutic Effects of Alpha-Particle Cancer Therapy Using Ac-225
-
Performance Testing of a Single-Cell Superconducting Accelerator Cavity
STORY LIST UTECが投資している方々やEXIT済み企業とのインタビューを掲載しています。